SCHEMBL2323010

SCHEMBL2323010

Brc1cnc2c(c1)ncn2CCN1CCCC1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.40
KDR P35968 3/20 0.37
TLR7 Q9NYK1 4/20 0.36
HRH3 Q9Y5N1 2/20 0.34
HRH1 P35367 1/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
PHF13 Q86YI8 1/20 0.34
L3MBTL3 Q96JM7 1/20 0.34
TLR9 Q9NR96 1/20 0.34
CSF1R P07333 1/20 0.34
HSD17B10 Q99714 2/20 0.33
ATM Q13315 2/20 0.33
HTR7 P34969 2/20 0.33
TSHR P16473 1/20 0.33
HTT P42858 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
LTA4H P09960 1/20 0.33
PTGS2 P35354 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4512898 0.82 SIGMAR1 (0.37) HDAC1KDRTLR7HRH3HRH1
SCHEMBL17488207 0.78 NPC1 (0.42) HDAC1CSF1RHSD17B10HTT
SCHEMBL20986036 0.78 ADORA2A (0.41) HDAC1CSF1RHSD17B10
SCHEMBL2325562 0.77 HDAC1 (0.56) HDAC1KDRHSD17B10HTR7TDP1
SCHEMBL18731878 0.73 HDAC1 (0.47) HDAC1KDRHRH3HRH1L3MBTL1
SCHEMBL24933390 0.73 GABRG2 (0.41) CSF1R
SCHEMBL12439999 0.72 MCHR1 (0.44) KDRATMHTTTDP1
SCHEMBL9905696 0.71 ADORA2B (0.36) CSF1RHSD17B10TDP1
SCHEMBL3389333 0.70 GRM5 (0.49) HRH3HSD17B10HTT
SCHEMBL1641114 0.70 HRH3 (0.44) HRH3L3MBTL1L3MBTL3TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8618132-B2 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2013-12-31 US disclosed
EP-1558578-B1 NOVEL ALKYNE COMPOUNDS HAVING AN MCH ANTAGONISTIC EFFECT AND MEDICAMENTS CONTAINING THESE COMPOUNDS BOEHRINGER INGELHEIM PHARMA (DE) 2013-03-13 EP disclosed
EP-2357173-A1 New alkyne compounds with MCH-antagonistic activity and medicaments containing them Boehringer Ingelheim Pharma GmbH & Co. KG (DE) 2011-08-17 EP disclosed
US-20090069282-A1 ALKYNE COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-03-12 US disclosed
US-7452911-B2 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2008-11-18 US disclosed
US-20040209865-A1 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069282-A1 ALKYNE COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS MCHR1, MCHR2, GPR119 HDAC1 2996/4885KDR 3272/4885TLR7 1644/4885
US-20040209865-A1 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds MCHR1, MCHR2, NPY1R HDAC1 3190/4885KDR 3661/4885TLR7 1940/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.